ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

PM54

A development code.

Its studies are led by PharmaMar.

Furthest: phase 2, since Jun 8, 20262 company-led studies, 2 open or runningNext primary completion: Dec 30, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
PharmaMar22 open or runningphase 2since Jun 8, 2026Mar 31, 2023Dec 30, 2026phase 1 · NCT05841563

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 31, 2023First study: phase 1 study in Advanced Solid TumorFirst studyNCT05841563 · 125 planned · United States, Belgium, Spain
  2. Jun 8, 2026Phase 2 study in Advanced MalignanciesPhase 2 reachedNCT07644039 · 119 planned · United States, Spain

Ahead

  1. Dec 30, 2026Primary completion: phase 1 study in Advanced Solid TumorNCT05841563
  2. Apr 2, 2029Primary completion: phase 2 study in Advanced MalignanciesNCT07644039

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07644039Advanced Malignancies · United States, Spain2RecruitingApr 2, 2029119
NCT05841563Advanced Solid Tumor · United States, Belgium, Spain1RecruitingDec 30, 2026125

How it is read

Names in the registry

  • “PM54”, 2 entries

Codes read as this program: PM54.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
    PM54 (PharmaMar): development program | ClinicalTrials.gg